Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZM-01 in X-linked Retinoschisis
NCT06066008Phase 1Completed
- Sponsor
- Zhongmou Therapeutics
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZM-01-L in X-linked retinoschisis (XLRS) (2 arms), sponsored by Zhongmou Therapeutics. Primary endpoints: Incidence of adverse events and serious adverse events at month 12 and Change in best corrected visual acuity at month 12. Started Sep 2022; status: completed.
02
Drugs
ZM-01-L
03
Conditions
X-linked retinoschisis (XLRS)
Beyond the preview
Go deeper on NCT06066008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066008.